Tempus AI (NASDAQ:TEM – Get Free Report) and Acadia Healthcare (NASDAQ:ACHC – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.
Earnings and Valuation
This table compares Tempus AI and Acadia Healthcare”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tempus AI | $1.51 billion | 7.96 | -$245.03 million | ($1.06) | -62.12 |
| Acadia Healthcare | $3.31 billion | 1.08 | -$1.10 billion | ($12.47) | -3.09 |
Tempus AI has higher earnings, but lower revenue than Acadia Healthcare. Tempus AI is trading at a lower price-to-earnings ratio than Acadia Healthcare, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
24.2% of Tempus AI shares are owned by institutional investors. 24.3% of Tempus AI shares are owned by company insiders. Comparatively, 1.2% of Acadia Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Tempus AI has a beta of 3.61, meaning that its stock price is 261% more volatile than the S&P 500. Comparatively, Acadia Healthcare has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.
Profitability
This table compares Tempus AI and Acadia Healthcare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tempus AI | -12.54% | -47.00% | -9.44% |
| Acadia Healthcare | -33.07% | 6.53% | 2.33% |
Analyst Recommendations
This is a summary of recent ratings for Tempus AI and Acadia Healthcare, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tempus AI | 1 | 10 | 11 | 0 | 2.45 |
| Acadia Healthcare | 2 | 4 | 8 | 1 | 2.53 |
Tempus AI currently has a consensus price target of $79.37, indicating a potential upside of 20.54%. Acadia Healthcare has a consensus price target of $32.54, indicating a potential downside of 15.43%. Given Tempus AI’s higher possible upside, analysts clearly believe Tempus AI is more favorable than Acadia Healthcare.
Summary
Tempus AI beats Acadia Healthcare on 9 of the 15 factors compared between the two stocks.
About Tempus AI
Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.
About Acadia Healthcare
Acadia Healthcare Company, Inc. is a U.S. provider of behavioral health services. The company operates facilities that treat mental health conditions and substance use disorders, serving patients through inpatient, residential and outpatient care. Its services include psychiatric hospitals, specialty treatment centers, residential programs and outpatient clinics. Care may include assessment, therapy, medication management and treatment for addiction, depending on the facility and program. Founded in 2005 and headquartered in Franklin, Tennessee, Acadia serves communities across the United States.
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
